You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

420 Results
Document
New
Feb 2025
Document
New
Feb 2025
Document
New
Feb 2025
Document
New
Feb 2025
Document
New
Feb 2025
Print This information is meant to help healthcare providers prepare for conversations with their patients ages 40 to 49 about whether breast...
Drug
Other Name(s): Sylvant®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
siltuximab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Les programmes cliniques d’Action Cancer Ontario sont mis en œuvre en collaboration avec les cliniciens des Programmes régionaux de cancérologie en...
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025

Pages